Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TRPM1
REST API REST API
Homo sapiens
TRPM1 is differentially expressed in 120 experiments: 64 organism parts: blood, skeletal muscle, ... (62 more);, 94 disease states: normal, melanoma, ... (92 more);, 34 cell types 85 cell lines 8 compound treatments and 55 other conditions.
Synonyms MLSN1, LTRPC1
Orthologs Trpm1 (Mus musculus)   TRPM1 (Gallus gallus)   Trpm1 (Rattus norvegicus)   TRPM1 (Bos taurus)   trpm1 (Danio rerio)   trpm1b (Danio rerio)   trpm1 (Xenopus laevis)   TRPM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, transport, calcium channel activity, ion transport, visual perception, membrane, ion channel activity, response to stimulus, integral to plasma membrane, receptor activity, integral to membrane, transmembrane transport, cellular response to light stimulus, calcium ion transmembrane transport
InterPro Term Ion_trans
UniProt Accession Q7Z4N2, D9IDV3, F8W865
Gene-Disease Assocation NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C
Search EB-eye ENSG00000134160
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MTAB-37, E-GEOD-21750, E-GEOD-20089, ... (11 experiments)

Factor Value U/D Experiments
Caki1
1
E-MTAB-37
SiHa
1
E-MTAB-37
CROAP2
1
E-MTAB-37
SUDHL5
1
E-MTAB-37
D341Med
1
E-MTAB-37
SW403
1
E-MTAB-37
79 more value(s).


Cell type

studied in E-GEOD-18811, E-GEOD-19069, E-GEOD-21668, E-GEOD-20033, E-GEOD-3920, ... (21 experiments)

Factor Value U/D Experiments
CD326negCD56+ cell
1
1
E-GEOD-21668
white blood cell
1
E-GEOD-2006
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
centroblast
1
E-TABM-702
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
plasma cell
1
E-MEXP-2360
28 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-5563, E-GEOD-16363, E-MEXP-66, ... (26 experiments)

Factor Value U/D Experiments
melanoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-7307
prostate carcinoma
2
E-MTAB-62, E-GEOD-7307
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
ganglioneuroblastoma
1
E-MTAB-62
AIDS-KS, KSHV-
1
1
E-MEXP-66
tumor
1
E-GEOD-19188
88 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-5824, E-MEXP-941 ... (5 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-412, E-GEOD-5824
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
bacterial endotoxin
1
1
E-GEOD-3284
control
30
1
E-GEOD-3284
glutamine
1
1
E-MEXP-941
trichostatin A
1
E-MEXP-1269
2 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-22593, E-GEOD-19293

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1103

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.467 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM